ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

GlaxoSmithKline and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaxoSmithKlineSanofi
studies on the registry4,1982,425
open to participants now136105
phase 3 studies under way7861
reach primary completion within a year6764
programswith a study of their own in two years88+17 named only80+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaxoSmithKlineSanofi
Phase 1

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%
28%
Phase 2

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%
Phase 3

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 4 programs whose next study reaches primary completion, 2 in phase 3

  1. Pn-MAPS30plusphase 1 · Nov 19 · NCT07428759
  2. dostarlimabapproved, new study · Nov 23 · NCT06567782
  3. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  4. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 1 program whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 10

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 29 in all. A program counts in each condition its studies name most.

ConditionGlaxoSmithKlineSanofi
Influenza, Humanboth · compare here
Respiratory Syncytial Virus Infectionsboth · compare here

GlaxoSmithKline in Respiratory Syncytial Virus Infections: 5 programs

  1. arexvyphase 3
  2. Adjuvanted RSVPreF3 vaccinephase 2
  3. hMPV_Y low dose vaccinephase 2
  4. RSV/hMPV_V low dose vaccinephase 2
  5. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Respiratory Syncytial Virus Infections in search

Sanofi in Respiratory Syncytial Virus Infections: 9 programs

  1. RSVt Vaccinephase 3
  2. RSV+HMPV vaccinephase 2
  3. RSV vaccine formulation 1 dosephase 2
  4. H5 Flu IMP 2phase 1
  5. Inosine Monophosphatephase 1

and 4 more — sign in to see them all

Their studies: Sanofi’s studies of Respiratory Syncytial Virus Infections in search

Asthmaboth · compare here

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Carcinoma, Non-Small-Cell Lungboth · compare here

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopicboth · compare here

GlaxoSmithKline in Dermatitis, Atopic: 2 programs

  1. camlipixantphase 3
  2. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Dermatitis, Atopic in search

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Lupus Erythematosus, Systemicboth · compare here

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Multiple Myelomaboth · compare here

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerativeboth · compare here

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

Nasal Polypsboth · compare here

GlaxoSmithKline in Nasal Polyps: 2 programs

  1. felcorekibartphase 3
  2. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Nasal Polyps in search

Sanofi in Nasal Polyps: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Nasal Polyps in search

Colorectal Neoplasmsboth · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Immune System Diseasesboth · compare here

GlaxoSmithKline in Immune System Diseases: 2 programs

  1. isatuximabphase 2
  2. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Immune System Diseases in search

Sanofi in Immune System Diseases: 2 programs

  1. amlitelimabphase 3
  2. belumosudilapproved, new study

Their studies: Sanofi’s studies of Immune System Diseases in search

Anemia, Hemolytic, Autoimmuneboth · compare here

GlaxoSmithKline in Anemia, Hemolytic, Autoimmune: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Anemia, Hemolytic, Autoimmune in search

Sanofi in Anemia, Hemolytic, Autoimmune: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Anemia, Hemolytic, Autoimmune in search

Anemia, Sickle Cellboth · compare here

GlaxoSmithKline in Anemia, Sickle Cell: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Anemia, Sickle Cell in search

Sanofi in Anemia, Sickle Cell: 2 programs

  1. rilzabrutinibphase 3
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Anemia, Sickle Cell in search

Arthritis, Rheumatoidboth · compare here

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Bronchiectasisboth · compare here

GlaxoSmithKline in Bronchiectasis: 1 program

  1. GSK3862995Bphase 2

Their studies: GlaxoSmithKline’s studies of Bronchiectasis in search

Sanofi in Bronchiectasis: 2 programs

  1. itepekimabphase 3
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Bronchiectasis in search

Diphtheriaboth · compare here

GlaxoSmithKline in Diphtheria: 2 programs

  1. Pentetic Acidphase 3
  2. dTpa vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Diphtheria in search

Sanofi in Diphtheria: 1 program

  1. DTaP-IPV-HB-PRP~T combined vaccinephase 3

Their studies: Sanofi’s studies of Diphtheria in search

Malariaboth · compare here

GlaxoSmithKline in Malaria: 2 programs

  1. as01ephase 2
  2. Dolutegravirapproved, new study

Their studies: GlaxoSmithKline’s studies of Malaria in search

Sanofi in Malaria: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Malaria in search

Measlesboth · compare here

GlaxoSmithKline in Measles: 2 programs

  1. MMRVNSphase 3
  2. MMRVNS vaccinephase 3

Their studies: GlaxoSmithKline’s studies of Measles in search

Sanofi in Measles: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Measles in search

Meningococcal Infectionsboth · compare here

GlaxoSmithKline in Meningococcal Infections: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Meningococcal Infections in search

Streptococcal Infectionsboth · compare here

GlaxoSmithKline in Streptococcal Infections: 2 programs

  1. Low dose Strep A Alumphase 1
  2. Low dose Strep A AS37phase 1

Their studies: GlaxoSmithKline’s studies of Streptococcal Infections in search

Sanofi in Streptococcal Infections: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Streptococcal Infections in search

Alzheimer Diseaseboth · compare here

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

Sanofi in Alzheimer Disease: 1 program

  1. SAR448851phase 2

Their studies: Sanofi’s studies of Alzheimer Disease in search

Autoimmune Diseasesboth · compare here

GlaxoSmithKline in Autoimmune Diseases: 1 program

  1. belantamabphase 2

Their studies: GlaxoSmithKline’s studies of Autoimmune Diseases in search

Sanofi in Autoimmune Diseases: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Autoimmune Diseases in search

Chronic Urticariaboth · compare here

GlaxoSmithKline in Chronic Urticaria: 1 program

  1. ozureprubartphase 2

Their studies: GlaxoSmithKline’s studies of Chronic Urticaria in search

Sanofi in Chronic Urticaria: 1 program

  1. BLU-808phase 2

Their studies: Sanofi’s studies of Chronic Urticaria in search

Diabetes Mellitus, Type 2both · compare here

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Gastrointestinal Stromal Tumorsboth · compare here

GlaxoSmithKline in Gastrointestinal Stromal Tumors: 1 program

  1. velzatinibphase 3

Their studies: GlaxoSmithKline’s studies of Gastrointestinal Stromal Tumors in search

Sanofi in Gastrointestinal Stromal Tumors: 1 program

  1. Avapritinibapproved, new study

Their studies: Sanofi’s studies of Gastrointestinal Stromal Tumors in search

Liver Cirrhosis, Biliaryboth · compare here

GlaxoSmithKline in Liver Cirrhosis, Biliary: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Liver Cirrhosis, Biliary in search

Sanofi in Liver Cirrhosis, Biliary: 1 program

  1. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Liver Cirrhosis, Biliary in search

Meningitis, Meningococcalboth · compare here

GlaxoSmithKline in Meningitis, Meningococcal: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Meningitis, Meningococcal in search

Sanofi in Meningitis, Meningococcal: 1 program

  1. MenACYW conjugate vaccineapproved, new study

Their studies: Sanofi’s studies of Meningitis, Meningococcal in search

Polycystic Kidney, Autosomal Dominantboth · compare here

GlaxoSmithKline in Polycystic Kidney, Autosomal Dominant: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Polycystic Kidney, Autosomal Dominant in search

Sanofi in Polycystic Kidney, Autosomal Dominant: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Polycystic Kidney, Autosomal Dominant in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: GlaxoSmithKline 65 of 88 · Sanofi 53 of 80 programs (26 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, Sanofi: 12).